Finasteride and minoxidil together: two drugs, two regulators, one scalp

Using both is common enough that the question arrives constantly, usually phrased as whether they work better together. The documents cannot answer that in the form it is asked, but they can settle four things that matter more than the headline: what each drug is, what a combination product legally is, what the FDA has said about the mixtures being sold, and what combining does to your ability to interpret your own experience.

Two unrelated mechanisms

Finasteride works on a hormone pathway: it inhibits the enzyme that converts testosterone into DHT, lowering DHT in blood and scalp. Minoxidil does not act on that pathway at all. It began life as a blood-pressure medicine, and the topical version sold over the counter for hair is a different regulatory product from the oral tablet, whose use for hair loss is off-label.

That difference is the whole argument for using both: they are not two attempts at the same thing. It is also why their side-effect profiles have almost nothing in common, which becomes important below. This site covers finasteride rather than minoxidil, so what follows sticks to the finasteride half and to what the documents say about the two of them meeting.

One consequence of the mechanical difference is worth stating early, because it is the strongest honest argument for the combination and it is rarely put properly. Finasteride reduces a driver of the problem; it does not itself push follicles into growing. A drug that acts on the follicle directly is doing a different job, so the two are not competing for the same effect and there is no pharmacological reason to expect them to cancel out. That is a reason the idea is plausible — not evidence that it delivers.

There is no approved combination product in the US

This is where the marketing and the regulatory record part company. The FDA's compounding alert of 22 April 2025 states that there are no FDA-approved topical products with finasteride alone or in combination with other ingredients, and it names the combination specifically: the agency is aware of compounders and telemedicine platforms marketing topical finasteride alone or combined with other active ingredients, such as finasteride combined with minoxidil, to treat hair loss.

So a single bottle containing both, in the US, is a compounded preparation that no regulator has assessed for safety, effectiveness or quality. The 32 adverse-event reports the FDA describes, and its finding that most of them said the effects persisted after stopping, cover exactly these products. The topical page goes through that alert in full.

The attribution problem

Here is the practical consequence that nobody selling a combination mentions. Start two treatments at once and you lose the ability to attribute anything that follows.

• Shedding in the early weeks is a documented complaint with topical minoxidil and is also reported by people starting finasteride. Two candidates, one observation.
• Scalp irritation points towards a topical and its carrier rather than a tablet — but if the topical contains both drugs, that narrowing gets you nowhere.
• Sexual or mood changes are documented in the finasteride record, including in the reports on compounded topicals. Attributing them correctly is the difference between stopping one medicine and stopping both.

A prescriber may have good reasons to start both together anyway. The point is that it is a real cost, it is rarely mentioned, and it is worth raising in the appointment.

Three different things people mean by "together"

The word covers three arrangements that are not equivalent in the eyes of any regulator, and conflating them is how the question gets answered badly.

1. A licensed tablet plus a licensed topical, used separately. Two approved products, each used within its own licence, in two different places on your routine. Whatever else is true, nothing here is unassessed.
2. A compounded topical containing both drugs. One bottle, no approval, the exact category the FDA's April 2025 alert is about — and the one being marketed hardest, because a single application is easier to sell than two.
3. Two oral medicines. Oral minoxidil for hair loss is itself off-label, which makes this a stack of two prescriber judgements rather than one, and firmly outside anything a website should be discussing.

If someone tells you that combining is well established, ask which of those three they mean. The answer usually changes the conversation.

What the evidence does and does not support

Trials of combined use exist in the literature, and a systematic review of finasteride-and-minoxidil mixtures against minoxidil alone is the sort of thing people cite at each other. We are not going to give you an effect size, for one reason: no regulator has assessed the combination, so there is no authoritative figure to quote, and quoting a single trial's number as though it settled the question is how this subject fills up with confident nonsense.

What can be said from the licensed documents: each medicine has a licence for hair loss in its own right in some jurisdictions, and neither licence covers the combination. Nothing in the documents suggests the two cancel out; nothing in them establishes that the benefits add up either.

What each record says about the other

Almost nothing, and that silence is informative. The FDA-approved labelling for finasteride describes its own trials against placebo; combined use with a topical is not part of the dossier it rests on. The safety reviews by the UK and EU regulators in 2024, 2025 and 2026 concern finasteride and dutasteride, and do not take up the question of combination with anything else.

The one place the two drugs appear in the same regulatory sentence is the FDA's compounding alert, and there they appear as a problem: a marketed mixture no agency has assessed. That is not an argument against a prescriber combining two licensed products thoughtfully. It is an argument against assuming that because a product exists, somebody official has checked it.

If you are considering both

The questions to take to a prescriber are unglamorous and specific. Is there a reason to start both at once rather than one and then the other? If something changes, how will we work out which one caused it? If a combined topical is proposed, which regulator assessed that formulation? And what is the plan for transfer to other people, given that the FDA's warning about inadvertent exposure applies to any uncoated topical containing finasteride?

The finasteride half of that conversation is laid out in full on the finasteride page, and if what you actually want is a side-by-side of the two drugs rather than a plan to use both, that comparison is here.